Fig. 1
From: Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer
Expression of FGD4 in prostate tumors changes with disease progression. a: Representative TMA images of the immunohistochemical analysis of FGD4 expression in benign prostatic hyperplasia (BPH) and prostate tumor tissues of different Gleason Grades, metastatic stages, and castration resistant (AI) stages. Images show weak staining in the basal cells in PIN (L) while strong staining in BPH, PIN (HI) tissues. A moderately higher expression of FGD4 could be noted in the luminal cells of prostate tumors with Gleason Scores 6 and 7, whereas a strong expression is evident in prostate tumor exhibiting more advanced stages. b: Comparative analysis of the percentage of strong, medium and low positive staining areas in BPH and prostate cancer tissues. c: Comparative analysis of the staining intensity across different prostate tissues. d: TCGA database analysis showing alteration in FGD4 DNA copy number and mRNA expression in neuroendocrine prostate cancer and prostate adenocarcinoma.